Stay updated on Tivozanib vs Sorafenib in Refractory RCC Clinical Trial
Sign up to get notified when there's something new on the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page.

Latest updates to the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page
- Check2 days agoChange DetectedUpdated page revision from v3.3.3 to v3.3.4 with no visible impact on content or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe study's Locations section has been expanded and reorganized to list participating sites across multiple countries and regions.SummaryDifference3%

- Check52 days agoChange DetectedThe Publications section now notes that PubMed publications are automatically populated and may not be about the study. The revision label changed from v3.2.0 to v3.3.2.SummaryDifference0.0%

- Check59 days agoChange DetectedNotice about government funding and NIH operating status was removed from the page's deletions section, with no changes to the study data or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check73 days agoChange DetectedThe new screenshot shows only minor user-interface adjustments, such as spacing and header alignment, with no changes to core trial information. There are no edits to the study title, conditions, interventions, eligibility criteria, enrollment, or outcome measures. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check102 days agoChange Detected- Added a government-operating-status notice and a link to official sources, indicating the page may have dynamic status information. - Updated version from v3.1.0 to v3.2.0, signaling a new release.SummaryDifference2%

Stay in the know with updates to Tivozanib vs Sorafenib in Refractory RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page.